CNTA

Centessa Pharmaceuticals

17.25 USD
+0.09
0.52%
Updated Dec 23, 12:34 PM EST
1 day
0.52%
5 days
2.99%
1 month
0.88%
3 months
10.79%
6 months
94.04%
Year to date
114.82%
1 year
116.98%
5 years
-20.69%
10 years
-20.69%
 

About: Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.

Employees: 75

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

256% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 9

175% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 16

116% more capital invested

Capital invested by funds: $804M [Q2] → $1.74B (+$936M) [Q3]

29% more funds holding

Funds holding: 80 [Q2] → 103 (+23) [Q3]

20% more funds holding in top 10

Funds holding in top 10: 5 [Q2] → 6 (+1) [Q3]

5.81% more ownership

Funds ownership: 78.75% [Q2] → 84.55% (+5.81%) [Q3]

88% less call options, than puts

Call options by funds: $99K | Put options by funds: $848K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$28
62%
upside
Avg. target
$28
62%
upside
High target
$28
62%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Guggenheim
Debjit Chattopadhyay
35% 1-year accuracy
7 / 20 met price target
62%upside
$28
Buy
Maintained
15 Nov 2024

Financial journalist opinion

Neutral
GlobeNewsWire
1 month ago
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
BOSTON and LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today reported financial results for the third quarter ended September 30, 2024, and provided a business update.
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
Positive
MarketBeat
2 months ago
Wake Up to This Biotech Stock That Still Has Big Potential Upside
Centessa Pharmaceuticals NASDAQ: CNTA is a biotechnology stock that has nearly doubled its value so far this year, and its run may not be over. Analysts at Morgan Stanley have just massively raised their price target for the company.
Wake Up to This Biotech Stock That Still Has Big Potential Upside
Neutral
GlobeNewsWire
2 months ago
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
Late-breaking poster presentation of non-human primate (NHP) data support ORX142 as novel drug candidate for the treatment of excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
Neutral
GlobeNewsWire
3 months ago
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
BOSTON and LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an upsized underwritten public offering of 15,254,237 of American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $14.75 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $225 million, before deducting underwriting discounts and commissions and offering expenses payable by Centessa. All ADSs sold in the offering were offered by Centessa. The offering is expected to close on or about September 16, 2024, subject to customary closing conditions. Centessa has also granted the underwriters a 30-day option to purchase up to an additional 2,288,135 ADSs at the public offering price, less underwriting discounts and commissions.
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
Neutral
GlobeNewsWire
3 months ago
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
BOSTON and LONDON, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $150 million of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of ADSs offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
Neutral
GlobeNewsWire
3 months ago
Nxera Pharma's Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
Tokyo, Japan and Cambridge, UK, 11 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – notes the announcement by Centessa Pharmaceuticals on 10 September 2024 reporting positive interim clinical data from its Phase 1 clinical trial with ORX750 in acutely sleep-deprived healthy volunteers. The full announcement from Centessa can be found by clicking here .
Nxera Pharma's Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
Positive
Investors Business Daily
3 months ago
Centessa Rockets To Three-Year High On $5 Billion Narcolepsy Opportunity
Centessa has a potential blockbuster narcolepsy treatment on its hands, an analyst said Tuesday as the biotech stock surged on test results.
Centessa Rockets To Three-Year High On $5 Billion Narcolepsy Opportunity
Neutral
GlobeNewsWire
3 months ago
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
BOSTON and LONDON, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced positive interim data from an ongoing Phase 1 trial of its highly potent and selective orexin receptor 2 (OX2R) agonist, ORX750, in acutely sleep-deprived healthy volunteers. ORX750 showed clinically meaningful and statistically significant improvements in mean sleep latency at the first two doses evaluated (1.0 mg and 2.5 mg) in the Maintenance of Wakefulness Test (MWT) compared to placebo. More specifically, the 2.5 mg dose was shown to restore normative wakefulness2 with a mean sleep latency of 32 minutes as measured by the MWT. ORX750 was also shown to have a favorable safety and tolerability profile with no observations of frequently reported on-target adverse events (AEs) associated with other OX2R agonists, and no cases of hepatotoxicity or visual disturbances across all three dose levels tested (1.0 mg, 2.0 mg, and 2.5 mg), as of the data cutoff date.1 Based on the interim data, the Company plans to rapidly advance ORX750 into Phase 2 studies in patients with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) beginning in the fourth quarter of 2024.
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
Neutral
GlobeNewsWire
3 months ago
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
ORX142 is currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive daytime sleepiness (EDS) ORX142 is currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive daytime sleepiness (EDS)
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
Neutral
GlobeNewsWire
4 months ago
Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
BOSTON and LONDON, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY. A fireside chat is scheduled for Wednesday, September 4th at 1:05 PM ET.
Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Charts implemented using Lightweight Charts™